Advertisement
Singapore markets closed
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,053.33
    -17.22 (-0.34%)
     
  • Dow

    38,351.74
    -151.95 (-0.39%)
     
  • Nasdaq

    15,667.76
    -28.88 (-0.18%)
     
  • Bitcoin USD

    64,618.39
    -1,929.56 (-2.90%)
     
  • CMC Crypto 200

    1,398.16
    -25.94 (-1.82%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,340.50
    -1.60 (-0.07%)
     
  • Crude Oil

    82.85
    -0.51 (-0.61%)
     
  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

10x Genomics Stock: Bull vs. Bear

10x Genomics Stock: Bull vs. Bear

Despite crushing the S&P 500 -- 180% to 63% -- since its September 2019 IPO, 10x Genomics' (NASDAQ: TXG) shares have only experienced 6% growth year to date. The company has rapidly become a cornerstone of biomedical research with its laboratory devices capable of profiling individual cells, but investors recently seem to have shrugged. Does the stock price just need a few quarters to catch up to its valuation?